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ExperienceInhaled therapies (bronchodilators  anti-inﬂammatory
therapy) are the cornerstones of obstructive lung disease man-
agement approaches.1,2 The aim of inhaled therapy is to deliver
agents directly to the lungs, thereby offering a more rapid onset
of action and a lower required dose than systemic administration,
minimizing the potential for treatment-related adverse effects.
Adherence to obstructive lung disease therapies involves patients
initiating their prescribed therapy, implementing it as prescribed
(ie, correctly administering the prescribed dose at the physician-
directed frequency), and persisting with treatment. Also central
to the therapeutic beneﬁt of inhaled therapies is their successful
administration, which requires patients to have knowledge and
understanding of (and ability to implement) the appropriate
inhaler technique required to optimize both the dispensed and
administered doses.3,4
A wide range of different devices are used to deliver short- and
long-acting bronchodilators and inhaled corticosteroid (ICS)
drugs (alone or in combination) for the management of asthma
and chronic obstructive pulmonary disease (COPD).1,2 Device
types include pressurized metered-dose inhalers (pMDIs), used
either alone or attached to spacers or valved holding chambers;
breath-actuated pressurized metered-dose inhalers (ie, BAIs); dry
powder inhalers (DPIs); or soft mist inhalers. There are more
than 200 drug-inhaler device combinations (branded items and
generic versions of existing brands) available.5 The wide variety
of inhaler devices available simultaneously presents both op-
portunities and challenges for patients and prescribers. Each class
of device (pMDI, BAI, DPI, soft mist inhaler) is associated with
a different approach to inhalation and, in turn, each device
within those classes may request speciﬁc nuances to the general
handling and inhalation technique to optimize delivery and
administration. pMDIs, for example, dispense a standardized
dose on depression of the canister and require the patients to
coordinate the timing of the canister depression and their
inhalation. BAIs try to minimize potential coordination errors
between the timing of the actuation and breath intake by using
the power of the patient’s breath to trigger the actuation. Breath
control is also key to the successful delivery of pMDIs (whether
breathe-actuated or not) as inspiratory ﬂow combines with the
energy of the pressurized dose delivery and, if too rapid, can
result in oropharangeal deposition of the medication, rather than
its delivery to the lungs. In contrast to pMDIs and BAIs, DPIs
do not contain a propellant and use the patients’ inspiratory ﬂow
as both the trigger and the actuation energy for the dispensed
dose. While DPIs therefore avoid the coordination issues pre-
sented by pMDIs, the fact that they are inspiratory ﬂowedriven
means that the dispensed dose is also ﬂow dependent. Further-
more, for each DPI there is a minimum inspiratory ﬂowrequired to achieve successful dispensing of the prescribed
therapeutic dose, something that may present a challenge for
patients with compromised lung function, particularly during an
exacerbation or, more generally, among elderly patients with
COPD and young children with asthma. Inhaled volume is
more important for capsule DPIs because the dose needs to be
emptied from the capsule during the inhalation.6 Moreover, a
dispensed dose does not equate to a delivered (or administered)
dose. Delivery also requires the volume of therapy leaving the
device to reach its target—the lungs—requiring appropriate
breath control, achievement of which varies substantially be-
tween different devices and device types (eg, slow vs sharp;
breath-hold).
As such, even when patients are accepting of their treat-
ment, and complicit in its initiation, their ability to imple-
ment the prescribed regimen successfully (which has inherent
implications for treatment persistence) is dependent on their
mastery of the speciﬁc inhaler-handling requirements (device
positioning/priming, actuation coordination, inspiratory ﬂow
rate, and breath control) of their prescribed device(s). The
situation is further complicated by the common use of
different inhaler device types for reliever and preventer ther-
apies, requiring patients to master (and maintain mastery of)
multiple techniques.6
Inadequate inhaler instruction and poor inhaler technique
represent one of the key determinants of asthma medication
adherence identiﬁed by the Assessment of the Safety in LABAs in
Asthma in Routine Care by combining Health-care databases
and direct patient follow up (ASTRO-LAB) through its exten-
sive review of the asthma adherence literature.7 This article
considers the implications of mode of delivery of asthma and
COPD therapy on medication adherence (and possible out-
comes), in particular the challenges medication inhalation poses
to successful implementation of treatment. A number of possible
approaches to identifying and addressing inhaler device errors are
also suggested.INHALED THERAPY—“TRYING, BUT FAILING”
The Ascertaining Barriers to Compliance taxonomy for
medication adherence was commissioned by the European
Union to standardize adherence-related terminology for clinical
and research use.8 It proposes a transparent nomenclature that
subdivides the traditional singular overarching research concept
of “adherence to medication” into 3 distinct elements, specif-
ically medication (1) initiation, (2) implementation, and
(3) persistence. The subdivision summarizes the sequence of
events within the medication process that have to occur for
patients to take their prescribed medication(s) successfully and
consistently (see Figure 1).8 Each element of the adherence
pathway may potentially be affected by prescribed mode of
therapy delivery.
Treatment initiation
Although it is often assumed that patients (at least) commence
therapy as prescribed, a community-based study of initiation
rates of chronic disease medications found that 28% of pre-
scriptions issued to adults for new chronic disease medications
were never dispensed and approximately one-quarter of patients
prescribed new asthma therapy failed to collect their ﬁrst
prescription.9
FIGURE 1. Illustration of the 3 key temporal steps involved in medication adherence. Reproduced from Vrijens et al,8 with permission
from the publisher.
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treatment initiation can be affected by a range of psychological
and practical barriers, among them denial of diagnosis, disease
awareness, lack of trust in health care professionals, medication
fears, cognitive ability, affordability, and access to therapy.10-12
In the context of asthma and COPD, mode of therapy
delivery can introduce an additional obstacle. Inhaled therapies
are the backbone of asthma and COPD management, but there
can be substantial stigma around the use of medication inhalers,
particularly in certain age and cultural groups. Inhaler stigmas
can deter initiation in some and (if collected) subsequent
implementation and persistence in others.13 The recent REcog-
nise Asthma and LInk to Symptoms and Experience (REALISE)
Asia study, which assessed patients’ perception of asthma control
and attitudes toward treatment in a multinational Asian popu-
lation, found that approximately half of all patients agreed with
statements that having inhalers was “embarrassing” or “a
nuisance.” Patients with uncontrolled asthma, in particular, felt
that it was an embarrassment (62.0%) or a nuisance (52.2%) to
use or even carry (56.7%) an inhaler in public, representing real
psychosocial barriers to initiation (and subsequent implementa-
tion and persistence) of inhaled therapy (see Table I).
Treatment implementation and persistence
Although treatment implementation and persistence are
2 distinct concepts—the ﬁrst relating to the longitudinal accu-
racy of administration of the prescribed dosing regimen over time
and second to the event of therapy discontinuation—these are
closely linked when considering the potential implications of
therapeutic delivery approach in asthma and COPD. The more
challenging the patients ﬁnd the mode of delivery of their
maintenance therapy, the greater their potential barriers to suc-
cessful implementation (administration and successful delivery)
and, in turn, the greater the potential for diminished treatment
outcomes.14,15
Inhaled medication. When it comes to the management of
asthma and COPD, the primary mode of medication delivery isvia inhalation. Therefore, in considering successful medication
adherence in a holistic way, this requires patients not only to
initiate and persist with their prescribed therapy but also to
implement it successfully: at the appropriate dose and dosing
frequency. This necessitates an understanding of the medication
prescribed and the ability to use the inhaled medication correctly.
The REALISE Asia study13 revealed a distinct lack of
understanding of the details and requirements of their treatment
regimen: a fundamental necessity to successful implementation
and an obvious barrier to successful medication management.
More than half (53%) of REALISE Asia patients were aware of
the need to use con-troller inhaler regularly to help manage their
asthma, but when asked about their controller inhalers only 20%
of the patients were able to identify them correctly (31% iden-
tiﬁed them incorrectly, and the rest did not know). Of those who
answered correctly, only 30% reported daily use of their
controller inhalers.
To compound the problem, despite continual inhaler redesign
and reﬁnement, incorrect (and inadequate) inhalation technique
persists,16-19 resulting in suboptimal medication implementation
and compromised asthma and COPD treatment outcomes.20 In
a review of 21 studies of pMDI use, the prevalence of poor
inhaler technique ranged from 14% to 90% (with an average of
50%).21 Furthermore, the use of multiple inhaler devices in an
individual patient has been shown to be associated with a higher
prevalence of errors than the use of single devices.22
The international Implementing “Helping Asthma in Real
People” (iHARP) initiative is the largest evaluation of routine
care inhaler technique conducted in asthma to date. A total of
5000 structured inhaler technique assessments were undertaken
in patients with moderate-to-severe asthma receiving ﬁxed-dose
combination ICS and long-acting beta-agonist therapy across
8 participating countries (the United Kingdom, France, Italy,
Spain, Sweden, Norway, Australia, and the Netherlands).23
The structured inhaler technique assessment was part of a wider
iHARP asthma review that included patient questionnaires, life-
style and current asthma control assessments (including factors that
may have an impact on asthma control), and a structured inhaler
TABLE II. The 12 most common DPI Diskus errors recorded in the
iHARP study22
1. Did not slide cover fully open
2. Dose lost after preparation because of holding downward
3. Shook inhaler device after dose preparation
4. Did not breathe out to empty lungs
5. Exhaled into the inhaler before inhalation
6. Did not put Diskus in mouth and seal lips around mouthpiece
7. Did not have head tilted such that chin is slightly upward
8. Insufﬁcient inhalation effort (inhalation is not fast, forceful from the
start, and as long as possible)
9. Did not inhale through mouth
10. No breath-hold follow inhalation (or holds breath for <3 s)
11. Patient had expired inhaler or empty inhaler
12. After inhalation did not replace cover
TABLE I. Patients’ attitudes toward inhalers/inhaler therapy in the REALISE Asia study12
Patients who strongly agree or tend to
agree with the following statements,
n (%) Overall (N [ 2467)
GINA-defined asthma control
Controlled (n [ 440) Partially controlled (n [ 802) Uncontrolled (n [ 1225)
I feel embarrassed using my asthma
inhaler in front of others
1162 (52.5) 140 (40.2) 328 (44.5) 694 (62.0)
I ﬁnd it a real nuisance having to use
my inhaler
1189 (48.2) 187 (42.5) 363 (45.3) 639 (52.2)
I feel embarrassed carrying my
asthma inhaler around with me
1294 (47.1) 177 (31.8) 357 (40.9) 760 (56.7)
I ignore my doctor’s instructions
about when and how often to take
my medication (inhaler)
895 (36.3) 101 (23.0) 246 (30.7) 548 (44.7)
I ﬁnd my inhaler difﬁcult to use 766 (31.1) 109 (24.8) 216 (26.9) 441 (36.0)
GINA, Global Initiative for Asthma.
Reproduced from Price et al,13 with permission from the publisher.
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appropriate. Frequency and inhalation errors were categorized for
patients prescribed ﬁxed-dose combinations of a bronchodilator
and ICS therapies, formulated in aDiskus or Turbohaler, or pMDI
(ﬂuticasone propionate and salmeterol combination; Seretide)with
or without a spacer. Analysis of the data revealed a high prevalence
(90%) of inhaler technique errors (1 error) across all devices: 84%
for their Diskus, 91% for Turbohaler, 92% for pMDI, and 91%
for the pMDI when used with a spacer. More than 20% of the
patients demonstrated at least 4 errors when using their controller
inhalers.24 The 12 most common errors recorded among Diskus
users in the iHARP initiative are summarized in Table II. Absence
of an inhaler technique review in the previous year was identiﬁed as
a predictor of error performance among Diskus users, as were
asthma-related hospitalization in the previous year, obesity, poor
asthma control the previous 4 weeks, and female sex.25
Further to this lies a potentially more complex relationship
and the clinical signiﬁcance of inhaler technique errors should
not be overlooked. In asthma, research suggests that higher
patient satisfaction with their asthma inhaler device is a signiﬁ-
cant predictor of more favorable clinical outcomes.26 In a pro-
spective patient and physician survey conducted to evaluate the
relationships between asthma outcomes, patient-reported satis-
faction with their inhaler device, and physician-reported adher-
ence, more favorable clinical outcomes were signiﬁcantly
associated with greater inhaler satisfaction (P ¼ .002) and higher
medication adherence (P ¼ .049). Attributes associated with
device satisfaction in the study included patient perceptions of
consistency in the amount of drug delivery to the lungs, ease of
use, and feedback about the number of remaining doses.
A similar association between inhaler satisfaction, medication
implementation, and clinical outcomes has also been observed in
COPD.27 A multinational real-world survey of clinicians (res-
piratory specialists and primary care physicians) and patients with
COPD (n ¼ 1443) found that patients’ overall satisfaction with
their maintenance inhaler was signiﬁcantly associated with their
medication implementation (as assessed by their physicians).
Patient-reported ease of inhaler use was among the factors that
inﬂuenced patients’ satisfaction with their maintenance therapy
delivery device. Signiﬁcant associations were observed between
increasing treatment compliance and fewer exacerbations and
hospitalizations. A direct association between inhaler satisfactionand fewer exacerbations was also reported.26 These results are
consistent with research that suggests that motivation for good
inhaler technique may be a key factor in long-term correct use.15
Inhaler device “switching”. With the recent and future
expiration of patent protections for several longstanding ICS and
bronchodilator therapies has come the development of bio-
equivalent, generic inhaled drugs and the potential for estab-
lished users of branded inhaled drugs to be switched to generic
formulations. Switching can lead to the use of new and/or
multiple inhalers and, consequently, new challenges and barriers
to effective dose administration and medication implementa-
tion.28-30 Such possibilities will need to be countered by
thoughtful training, retraining, and ongoing education to avoid
loss of disease control and stability and recognition that
switching asthma therapy without an accompanying consultation
has been shown to lead to worsening asthma outcomes.31
Inhaler device “mixing”. Because many patients with
asthma and/or COPD are prescribed both inhaled reliever
therapy (ie, short-term bronchodilators for symptom relief) and
inhaled maintenance therapy (eg, corticosteroids and/or bron-
chodilators for long-term risk management), the implications of
“device mixing” (ie, the prescription of>1 inhaler device type for
a single patient) must be considered. Good medication
FIGURE 2. Pre and post bronchodilator spirometry: severe obstructive pattern with significant response to short acting beta 2 agonist.
J ALLERGY CLIN IMMUNOL PRACT
SEPTEMBER/OCTOBER 2016
828 BRAIDO ETALimplementation in the context of multiple devices requires pa-
tients to master (and maintain mastery of) more than 1 inhaler
technique successfully, something that is further complicated if
different classes of device are involved. Indeed, a negative asso-
ciation has been shown between maintenance inhaler number
and patients’ medication implementation (patients prescribed
2 maintenance inhaler devices have been shown to be 34% less
likely to be “adherent” and to have a 40% higher treatment
discontinuation rate than are patients taking a single long-acting
inhaled drug),32 and use of mixed/different inhaler device types
for maintenance and reliever therapies is associated with higher
rates of severe exacerbations and lower odds of achieving asthma
control in patients with asthma initiating ICS therapy.33
To mitigate against such challenges in the future, new gen-
erations of devices aim to limit the number of inhaler maneuvers
necessary and try to support successful administration through
visual and auditory feedback systems. In addition, several device
manufacturers have developed an inhaler device that will serve as
a standard “platform” for all the drugs commercialized by the
company, enabling ﬂexibility in terms of drug, and drug dosage,
while retaining a standardized inhaler tool across the inhaled
therapy portfolio. However, the availability of reliever therapies
(eg, salbutamol) in these devices remains limited owing to a lack
of commercial viability resulting from regulation of short-acting
beta-agonist drug costs.
Oral medication. The challenges patients face in successfully
implementing inhaled therapy can be inferred from the results of
Price et al’s14 pragmatic single-blind randomized controlled trial
and economic evaluation of the use of leukotriene receptorantagonists (LTRAs) in primary care at steps 2 and 3 of the
national asthma guidelines (the ELEVATE study, a pragmatic
single-blind randomized controlled trial and economic evaluation
of the use of leukotriene receptor antagonists in primary care at
steps 2 and 3 of the national asthma guidelines). At the primary
2-month outcome period, initiation of LTRAs was equivalent to
guideline-recommended ICS therapy in terms of the primary
outcome Mini Asthma Quality of Life Questionnaire. By the 2-
year secondary outcome period, although true equivalence was
not shown, no signiﬁcant differences were found between
LTRAs and ICS for any of the primary or secondary outcome
measures.
One of the likely reasons the ELEVATE authors offered for
the equivalence ﬁnding was the higher rate of adherence to
LTRA compared with ICS therapy (median adherence rates of
65% and 41%, respectively). Although ICS is more efﬁcacious
than LTRA therapy when implemented optimally in randomized
clinical trials (RCTs) environment,14 the ELEVATE data suggest
that starting anti-inﬂammatory therapy as LTRA is noninferior
to ICS when initiated with a less onerous ecology of care than
used in classical RCTs. As such, LTRA could be considered as a
possible alternative to initiating anti-inﬂammatory therapy as
ICS in patients with asthma, particularly in those with a noted
preference for oral over inhaled therapy and/or who struggle to
master inhaler device technique.
Dosing frequency. Understanding patient preference is not
only important with respect to mode of therapy delivery but also
when considering frequency of administration because both are
integral to successful medication implementation.34 Some studies
FIGURE 3. Future research needs to support a paradigm shift in obstructive lung disease management—away from consideration of
adherence and inhaler technique as discrete entities and toward a more integrated concept of “quality use of respiratory medications.”
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reducing the frequency of dosing, may improve medication
implementation.35 Such considerations are of particular relevance
in patients with comorbidities (and therefore generally more
relevant in the management of COPD than asthma) who may
already face challenges in coordinating dosing of coexisting
therapies. Indeed, in a questionnaire-based assessment of dosing
frequency prevalence in 3731 patients with asthma and 2138
patients with COPD, approximately half the patients in each
cohort indicated a preference for once-daily controller therapy.36
Across both asthma and COPD cohorts, preference for once-
daily controller medication was signiﬁcantly associated withpoor implementation and higher medication-related concerns.
Yet the drivers for patient preference appeared to vary between
conditions, with preference for once-daily therapy in patients
with asthma being associated with good control and low self-
perceived controller medication need while, in contrast, prefer-
ence among patients with COPD was associated with high self-
perceived need for controller medication.
The study ﬁndings suggest that there are differences between
people with asthma and those with COPD and, moreover, that
inherent differences in the nature of asthma and COPD may
inﬂuence patient perceptions (and behaviors) toward their pre-
scribed therapies. Asthma symptoms are episodic and patients
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COPD symptoms are constant, progressive, and often debili-
tating. Furthermore, patients with COPD tend to have multiple
comorbidities, which may mean that they are already on a
complex cocktail of drugs and are keen to simplify their treat-
ment regimen, where possible.
The limited evidence of the effect of dosing regimen on res-
piratory medication adherence suggests that once-daily admin-
istration may be associated with better implementation than
twice-daily therapy in asthma.35 This is consistent with obser-
vations in other chronic conditions, such as diabetes and HIV.37
Such ﬁndings suggest the importance of understanding patients’
beliefs about their treatment—in particular their self-perceived
necessity and concerns about therapy—in selecting the opti-
mum management approach (including controller therapy and
dosing regimen) so as to optimize treatment initiation, imple-
mentation, and discontinuation.ROLE OF THE HEALTH CARE PROFESSIONAL
Patients’medication beliefs and preferences are associated with
their adherence to asthma and COPD therapies38-40 and
treatment outcomes depend not only on the availability of
medications but also on their appropriate prescribing and suc-
cessful administration. Poor adherence to asthma and COPD
controller medications is associated with higher rates of exacer-
bations and impaired quality of life, resulting in increased health
care costs from unnecessary escalations in therapy and avoidable
hospitalizations.41-44
Many patients choose not to take their medication because
they perceive it to be unnecessary or because they are concerned
about potential adverse effects. These concerns are limited not
only to the experience of local ICS-related adverse effects but also
to more abstract concerns about future medication dependency.
Previous work has reported a direct relationship between
patients’ beliefs about ICS (their need for it and related concerns)
and reﬁll-based ICS implementation.40 Similarly, the odds of
ICS implementation have been shown to be higher among
patients who felt that using ICS when asymptomatic was
important and in patients conﬁdent in using their controller
therapy, but lower in those who reported concerns about adverse
effects of ICS or who felt that their regimen was hard to follow.34
Similarly, in patients with COPD, patients’ conviction of the
importance of treatment is reported to have a signiﬁcant positive
inﬂuence on adherence.45
The health care practitioner has an instrumental role to play in
eliciting and addressing patients’ attitudes and beliefs about
therapy in such a way as to individualize treatment choice and
tailor education appropriately with a view to optimizing adher-
ence (see article by van Boven et al46 in this issue). Despite best
efforts, time and resource restrictions may result in patients and/
or their caregivers not feeling that they receive all the information
they feel they need about their condition and prescribed medi-
cations, with the potential for patient disenfranchisement early in
the medication adherence pathway.47
The concept of patient-centered care is highlighted by the case
study described in Figure 2, which summarizes the characteristics
of a patient referred to a specialist asthma service in the
Netherlands and illustrates how lack of patient engagement and
critical interrogation of patient details by primary care clinicians
can result in escalation of patients’ care and unnecessary use ofavailable health care resources. The 52-year-old female patient
has asthma and bronchitis (but COPD is not proven) with very
poor Medical Research Council dyspnea, Asthma Control
Questionnaire, and Clinical COPD Questionnaire scores of 5,
4.8, and 4.8, respectively. Before presentation at the severe
asthma service, she had been prescribed short-acting broncho-
dilator therapy, ICS, and different long-acting bronchodilator
therapies. Although her spirometry readings were also poor, she
showed good reversibility and, when asked, she admitted to only
occasional use of her medications. Moreover, when assessed she
performed 4 inhalation technique errors. A lack of “clinical
inertia” within the primary care setting had resulted in an esca-
lation of bronchodilator therapy from short- to long-acting,
perhaps reﬂecting the possible presence of the asthma-COPD
overlap syndrome, but overlooking the key issue of poor
implementation, with respect to both prescribed treatment fre-
quency and effectiveness of inhaler administration.
TOWARD OPTIMIZED ADHERENCE TO
RESPIRATORY MEDICATION
Asthma and COPD guidelines underline the importance of
correct inhaler technique training and frequent inhaler technique
checks.1,2,48 Yet assessment of inhaler technique knowledge
among health care professionals reveals limited expertise, with
39% to 85% of nurses, doctors, and respiratory therapists unable
to demonstrate and brief patients in the proper use of their
devices.49-51 In an assessment of inhaler technique in health care
professionals working on a respiratory ward of a major metro-
politan hospital in Australia (and the subsequent impact of
training on their proﬁciency), not 1 of the 25 health care pro-
fessional (pharmacists, n ¼ 11; nurses, n ¼ 16) demonstrated
correct inhaler technique before training.52 The challenge of
correct inhaler training by health care professionals is also likely
exacerbated by time constraints in clinical practice: it has been
reported that 1 in every 4 patients does not receive any verbal
instruction and nearly 1 in 2 receives less than 10 minutes of
inhaler training.51
Ability to successfully administer prescribed therapy has a
direct effect not only on medication implementation but also on
perceived treatment beneﬁt and patients’ willingness to persist
with therapy. The importance of optimizing therapy delivery is
also stressed in the World Allergy Organization and International
Association of Asthmology (INTERASMA) “Manifesto on
adherence to asthma treatment in respiratory allergy” (also
endorsed by Allergic Rhinitis and Its Impact on Asthma and the
Global Allergy and Asthma European Network).53 The mani-
festo recommends that adherence be prioritized within patient
education and advises that while adherence is considered a
“moral responsibility” of the patient, health care professionals
should be empathetic rather than condemnatory and provide
patients with support and education. In an age of emerging
technologies and “smart inhaler” devices and monitors, the
World Allergy Organization promotes the use of technology-
based adherence interventions, by both patients and health care
professionals, to help monitor implementation and motivate
improved adherence.53
UNMET RESEARCH NEEDS
This review brings together existing evidence on the challenges
different modes and approaches to the delivery of asthma and
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treatment satisfaction, medication adherence (initiation, imple-
mentation, and persistence), and clinical outcomes. There
remain many related research needs that warrant further explo-
ration in well-designed studies (particularly real-life studies)
targeted at speciﬁc steps of the temporal adherence pathway and
using appropriate research methods. Among the future needs
identiﬁed by Price et al3 for asthma were the gaps in inhaler
education and knowledge; the health economic and clinical
outcome evaluations associated with inhaler technique; and the
impact of cultural beliefs on inhaler use. Additional research
needs relating to asthma and COPD medication delivery and
adherence, discussed or implied within this review, are proposed
in Figure 3. At their core is the need for a more holistic and
integrated approach to treatment optimization that combines
generic device education delivered with more targeted
interventions to promote overall quality use of medications. To
achieve this, there is a need for better understanding of how
adherence and inhaler technique are conceptually related
(whether they are distinct or should be combined as part of
“quality use of medications” approach); a need to develop more
generic educational interventions that transcend device-speciﬁc
challenges, device switching, and combination use, and a need
to improve understanding of distinct adherence and technique
behaviors within key patient subgroups (eg, pediatrics, adoles-
cents, adults, and elderly) and at different disease stages in order
to inform the development of more targeted interventions.CONCLUSIONS
The efﬁcacy of therapies for asthma and COPD has been
repeatedly demonstrated in the RCT setting, yet both conditions
are often inadequately managed in everyday routine care.1,2 The
difference in efﬁcacy and effectiveness proﬁles of respiratory
therapies results from strict RCT design. These studies exclude
many of the real-life factors that interact with idealized efﬁcacy
when therapies are used in the routine care environment, such as
comorbid conditions (eg, diabetes, gastroesophageal reﬂux, and
cardiovascular disease), wide ranging lifestyle factors (eg, smoking
and trigger exposures), and varying levels of treatment adherence.
RCTs may positively bias adherence to therapy through their
highly interventional nature, leading to possible “white coat
adherence” (improved patient adherence to treatment around
clinic visits),54 Hawthorne effects,55 and training and retraining
of effective technique in the case of inhaled therapies.
As inhaled therapies form the backbone of the therapeutic
management of asthma and COPD, it is important to prescribe
an inhaler that the patient can and will use.6 The identiﬁcation of
patients’ attitudes (and potential concerns) to inhalers should
also be explored to ensure there are no obvious barriers to
initiation and use of the prescribed therapy. Thereafter, it is
crucial that patients are instructed as to the correct use of their
inhalers and that their technique is regularly checked and
corrected/retrained, as required. Failure to do so will result in
suboptimal implementation (failure to receive the prescribed
dose at the frequency intended), suboptimal treatment outcomes,
and potential early discontinuation.
Inhaler technique is not always well understood by health care
professionals, but clinicians should aim to have knowledge of
several inhaler devices (and device types) so that they can tailordevice selection to the individual needs, preferences, and capa-
bilities of their patients.6 The list of common Diskus errors
identiﬁed by the iHARP investigators24 can be used by practicing
clinicians as an aide memoire (or reference checklist) when con-
ducting relevant inhaler technique assessments. Identiﬁcation of
suboptimal inhaler use should prompt retraining and/or a dis-
cussion with the patients as to their perceived challenges using
their device and alternative treatment options that may be more
suitable. Alternatives should include consideration of simpliﬁ-
cation of treatment regimen (such as use of same type inhalers for
reliever and controller medications; move to combination ther-
apies to reduce the number of different inhalers being used;
switching to once-daily therapies) or even possible use of oral
therapies, in line with guideline recommendations.1,2
To optimize adherence to therapy (initiation, implementation,
and persistence), treatment decisions should be conducted in
collaboration with the patient and should take into consideration
their lifestyle factors (eg, work patterns/shifts that may be a
barrier to frequent dosing), demographic characteristics (eg, age;
see article by Costello et al56 in this issue), and clinical factors
(eg, comorbidities and potentially complex polypharmacy regi-
mens). In this way, treatment choice and its mode of delivery can
be tailored to individual patient needs and preferences. There-
after, it should be frequently assessed (eg, as annual reviews) and,
where possible, digitally monitored so as to prompt as-needed
education, retraining, and/or adjustment and optimize real-
world treatment outcomes.
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